- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Elranatamab, +19 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Relapsed Refractory Multiple Myeloma (RRMM)
Explore clinical trials studying Relapsed Refractory Multiple Myeloma (RRMM). Study availability and eligibility vary by location and protocol.
9 public trials
7 recruiting studies
Relapsed Refractory Multiple Myeloma (RRMM) trial results
Recruiting
ELISA in Relapsed/Refractory MM
NCT06832865
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
NCT07455851
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Prince of Wales Hospital Randwick, New South Wales, Australia
- Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
- Royal Adelaide Hospital Adelaide, South Australia, Australia
- Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
NCT07032714
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
NCT05730036
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- University of California Los Angeles (UCLA) Los Angeles, California, United States
- University of Florida Division of Sponsored Programs Gainesville, Florida, United States
- University of Kentucky, Markey Cancer Center Clinical Research Organization Lexington, Kentucky, United States
- Norton Cancer Institute Louisville, Kentucky, United States
NCT06645678
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- National University Hospital (NUH) Singapore
- Singhealth Duke NUS blood cancer center Singapore
- Chonnam National University Hwasun Hospital Hwasun, South Korea
- Asan Medical Center, University of Ulsan College of Medicine Seoul, South Korea
Recruiting
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
NCT06920251
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Seoul National University Hospital Seoul, South Korea
Not yet recruiting
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
NCT07831122
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- Cross Cancer Institute Edmonton, Alberta, Canada
- QEII Health Sciences Centre Halifax, Nova Scotia, Canada
- London Health Sciences Centre London, Ontario, Canada
- The Ottawa Hospital - General Hospital Ottawa, Ontario, Canada
Not yet recruiting
BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM
NCT07407010
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
Not specified